Lucia Enriquez-Rodriguez

Mrs. Lucia Enriquez-Rodriguez


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CACristina Aparicio
Cristina Aparicio
MBMarina Belver
Marina Belver
LELucia Enriquez-Rodriguez
Lucia Enriquez-Rodriguez
FEFrancisco Espeso
Francisco Espeso
LNLucía Núñez
Lucía Núñez
MGMargarita González-Vallinas
Margarita González-Vallinas
Colorectal cancer (CRC) is a global public health problem as it is the third most prevalent and the second most lethal cancer worldwide. Major efforts are underway to understand its molecular pathways as well as to define the tumour-associated antigens (TAAs) and tumour-specific antigens (TSAs) or neoantigens, in order to develop an effective treatment. Cell therapies are currently gaining importance, and more specifically chimeric antigen receptor (CAR)-T cell therapy, in which genetically modified T cells are redirected against the tumour antigen of interest. This immunotherapy has emerged as one of the most promising advances in cancer treatment, having successfully demonstrated its efficacy in haematological malignancies. However, in solid tumours, such as colon cancer, it is proving difficult to achieve the same results due to the shortage of TSAs, on-target off-tumour effects, low CAR-T cell infiltration and the immunosuppressive microenvironment. To address these challenges in CRC, new approaches are proposed, including combined therapies, the regional administration of CAR-T cells and more complex CAR structures, among others. This review comprehensively summarises the current landscape of CAR-T cell therapy in CRC from the potential tumour targets to the preclinical studies and clinical trials, as well as the limitations and future perspectives of this novel antitumour strategy.

30 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CACristina Aparicio
Cristina Aparicio
Mónica QueipoMónica Queipo
Mónica Queipo
MBMarina Belver
Marina Belver
FEFrancisco Espeso
Francisco Espeso
JSJulia Serna
Julia Serna
MGMargarita González-Vallinas
Margarita González-Vallinas
Background/Objectives: Chimeric Antigen Receptor (CAR)-T cell therapy has demonstrated impressive clinical results against hematological malignancies. However, currently commercialized CAR-T therapies are designed for autologous use, which entails some disadvantages, including high costs, manufacturing delays, complex standardization, and frequent production failures due to patient T cell dysfunction. Moreover, their CARs target one specific antigen, increasing the probability of antigen-negative tumor relapses. To overcome these limitations, we developed a novel NKG2D CAR-T cell therapy for allogeneic use with broad target specificity, as this CAR targets eight different ligands commonly upregulated in both solid and hematological tumors. Additionally, the manufacturing process was optimized to improve the phenotypic characteristics of the final product. Methods: Multiplex CRISPR/Cas9 technology was applied to eliminate the expression of TCR and HLA class I complexes in healthy donor T cells to reduce the risk of graft-versus-host disease and immune rejection, respectively, as well as lentiviral transduction for introducing the second-generation NKG2D-CAR. Moreover, we sought to optimize this manufacturing process by comparing the effect of different culture interleukin supplementations (IL-2, IL-7/IL-15 or IL-7/IL-15/IL-21) on the phenotypic and functional characteristics of the product obtained. Results: Our results showed that the novel CAR-T cells effectively targeted cervicouterine and colorectal cancer cells, and that those manufactured with IL-7/IL-15/IL-21 supplementation showed the most suitable characteristics among the conditions tested, considering genetic modification efficiency, cell proliferation, antitumor activity and proportion of the stem cell memory T cell subset, which is associated with enhanced in vivo CAR-T cell survival, expansion and long-term persistence. Conclusions: In summary, this new prototype of NKG2D CAR-T cell therapy for allogeneic use represents a promising universal treatment for a wide range of tumor types.

10 May 2023
Verified
Conference Paper
Closed access
JMJose Luis Pedraz Muñoz
Jose Luis Pedraz Muñoz
NANoha Attia
Noha Attia
Mohamed Ahmed MashalMohamed Ahmed Mashal
Mohamed Ahmed Mashal
IGIdoia Gallego
Idoia Gallego
LELucia Enriquez-Rodriguez
Lucia Enriquez-Rodriguez
IPIvan Maldonado Pérez
Ivan Maldonado Pérez
Bektore ez-biral lipidikoak garatzeko erabiltzen diren teknikak eta hauen garrantzia etorkizunerako produkzioaren informazio-fitxa

19 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJosé David Celdrán López
José David Celdrán López
LHLawrence Humphreys
Lawrence Humphreys
MVMaria Jose Verdú
Maria Jose Verdú
DGDesiree Gonzalez
Desiree Gonzalez
CSCristina Soto-Sánchez
Cristina Soto-Sánchez
EFEduardo Buglioni Fernandez
Eduardo Buglioni Fernandez
Background: Gene therapy has experienced significant development since its origin decades ago, resulting in therapies for a wide range of diseases. In this context, optogenetics has emerged as a promising therapy for treating diseases in a precise spatiotemporal way using light. Transporting optogenetic genes to target cells is achieved using viral vectors, specifically AAV vectors. These vectors present limited cargo capacity, and a large percentage of the population carries AAV neutralizing antibodies. In this regard, lipid nanoparticles can overcome some of the previously mentioned problems of AAV vectors, making them prime candidates for optogenetic delivery. Methods: In this study, we evaluated their suitability for the delivery of the ChrimsonR plasmid in neurons in vitro. Results: In rat cortical neurons, in most of the concentrations tested, there was no reduction in several neuron morphological parameters that we measured when compared to another non-viral nanoparticle called lipofectamine. Transfection efficiency was significantly higher compared to lipofectamine in almost all treatments. Further in vitro analysis showed that electrophysiological parameters were altered, with reduced signal amplitudes; however, cell viability assays showed no decline in cell viability. Conclusions: These results demonstrate that lipid nanoparticles represent a promising non-viral platform for optogenetic delivery, though formulation optimization is required to achieve full functional efficacy.